| Rockefeller Univ–Lumicks: microscope, 202201 supply of Quadrupole C-Trap system to lab of Prof Michael O’Donnell |
2022-01-12 |
| Creoptix–Spectris: investment, 202201 acquisition of Creoptix AG by Malvern Panalytical |
2022-01-11 |
| Antigon–Analis: investment, 202112 financing round totalling €1.5m incl new investor Analis SA |
2021-12-22 |
| Antigon–BeAngels: investment, 202112 financing round totalling €1.5m incl existing investor Be Angels |
2021-12-22 |
| Antigon–HTP Europe: investment, 202112 financing round totalling €1.5m incl new investor HTP Europe |
2021-12-22 |
| Antigon–Sambrinvest: investment, 202112 financing round totalling €1.5m incl existing investor Sambrinvest |
2021-12-22 |
| Antigon–SEVERAL: investment, 202112 financing round €1.5m with Sambrinvest + BeAngels + Analis + HTP Europe |
2021-12-22 |
| Alesta Therapeutics–Thuja Capital: investment, 202112 existent investment of Thuja Capital Healthcare Fund III |
2021-12-21 |
| EsoBiotec–Thuja Capital: investment, 202112 existent investment of Thuja Capital Healthcare Fund III |
2021-12-21 |
| Thuja Capital–SEVERAL: investment, 202112 final closing of Thuja Capital Heathcare Fund III at €76m incl investor EIF |
2021-12-21 |
| NorthSea Therapeutics–BioGeneration Ventures: investment, 202112 financing round Series C totalling $80m incl existing + co-investor BGV |
2021-12-17 |
| NorthSea Therapeutics–Forbion: investment, 202112 financing round Series C totalling $80m incl existing + co-lead investor Forbion |
2021-12-17 |
| NorthSea Therapeutics–Hercules Capital: investment, 202112 financing round Series C totalling $80m incl new + co-investor Hercules Capital |
2021-12-17 |
| NorthSea Therapeutics–New Science Ventures: investment, 202112 financing round Series C totalling $80m incl existing + co-investor New Science |
2021-12-17 |
| NorthSea Therapeutics–Novo Group: investment, 202112 financing round Series C totalling $80m incl existing + co-investor Novo Seeds |
2021-12-17 |
| NorthSea Therapeutics–OTHER: investment, 202112 financing round Series C totalling $80m incl new + co-investor large managed care organisation |
2021-12-17 |
| NorthSea Therapeutics–SEVERAL: investment, 202112 financing round Series C $80m co-led by Ysios Capital + Forbion Growth |
2021-12-17 |
| NorthSea Therapeutics–Sofinnova: investment, 202112 financing round Series C totalling $80m incl existing + co-investor Sofinnova |
2021-12-17 |
| NorthSea Therapeutics–VenBio: investment, 202112 financing round Series C totalling $80m incl existing + co-investor VenBio |
2021-12-17 |
| NorthSea Therapeutics–Ysios Capital: investment, 202112 financing round Series C totalling $80m incl new + co-lead investor Ysios Capital |
2021-12-17 |
| Anaveon–Forbion: investment, 202112 financing round Series B totalling CHF110m incl new + lead investor Forbion |
2021-12-16 |
| Anaveon–SEVERAL: investment, 202112 financing round Series B CHF110m with new + lead investor Forbion |
2021-12-16 |
| Argobio–GeneCode: GDNF mimetics, 202112– collab development with up to €3m funding for incubation phase by Argobio to incorporate new biotech company |
2021-12-16 |
| Bioqube Ventures–Metrion Biosciences: drug discovery services, 202112– collab project to identify ion channel inhibtors for autoimmune diseases |
2021-12-16 |
| Bioqube Ventures–Optimum Strategic Communications: public relations, 202112 service existent by Optimum |
2021-12-16 |
| Synerkine Pharma–Flerie Invest: investment, 202112 financing round Series A extension totalling €3.5m incl new + lead investor Flerie Invest |
2021-12-16 |
| Synerkine Pharma–SEVERAL: investment, 202112 financing round Series A extension €3.5m from Flerie Invest + Thuja Capital + Utrecht Holdings |
2021-12-16 |
| Synerkine Pharma–Thuja Capital: investment, 202112 financing round Series A extension totalling €3.5m incl existing + co-investor Thuja Capital |
2021-12-16 |
| Synerkine Pharma–Univ Utrecht: investment, 202112 financing round Series A extension totalling €3.5m incl existing + co-investor Utrecht Holdings |
2021-12-16 |
| Biogazelle–CellCarta: investment, 202112 acquisition of Biogazelle by CellCarta |
2021-12-14 |
| BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme |
2021-12-14 |
| Sirius Medical–SEVERAL: investment, 202112 financing round Series A 2nd closing €na with BOM Brabant Ventures + Holland Capital et al |
2021-12-14 |
| Corteria Pharmaceuticals–SEVERAL: investment, 202112 seed financing round €12m led by Kurma Partners |
2021-12-09 |
| Corteria Pharmaceuticals–V-Bio Ventures: investment, 202112 seed financing round totalling €12m incl co-investor V-Bio Ventures |
2021-12-09 |
| Forbion European Acquisition Corporation–SEVERAL: investment, 202112 SPAC US IPO $110m with 11m units at $10/unit |
2021-12-09 |
| Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures |
2021-12-08 |
| HypnoVR–SEVERAL: investment, 202112 financing round Series A €4.5m led by Theodorus |
2021-12-07 |
| HypnoVR–Theodorus: investment, 202112 financing round Series A totalling €4.5m incl new + lead investor Theodorus |
2021-12-07 |
| AviadoBio–SEVERAL: investment, 202112 financing round Series A £58.6m led by NEA + co-led by Monograph Capital |
2021-12-03 |
| Novartis–UCB: Parkinson drugs, 202112– collab up to $1.5b with $150m upfront ww developm + commercialisation of UCB0599 + option for UCB7853 |
2021-12-02 |
| Sotio–PPF Group: investment, 202112 new €280m funding for Sotio Biotech from owner PPF Group |
2021-12-02 |
| Amarna Therapeutics–C4 Holding: investment, 202112 financing round totalling €4m incl existing investor C4 Holding BV |
2021-12-01 |
| Amarna Therapeutics–Flerie Invest: investment, 202112 financing round totalling €4m incl existing investor Flerie Invest AB |
2021-12-01 |
| Amarna Therapeutics–Netherlands (govt): credit, 202112 innovation credit €1m from RVO |
2021-12-01 |
| Amarna Therapeutics–SEVERAL: investment, 202112 financing round €4m from existing investors C4 Holding BV + Flerie Invest AB |
2021-12-01 |
| HotSpot Therapeutics–Life Sciences Partners: investment, 202111 financing round Series C totalling $100m incl new + significant co-investor LSP |
2021-11-29 |
| HotSpot Therapeutics–SEVERAL: investment, 202111 financing round Series C $100m led by Pivotal BioVenture Partners |
2021-11-29 |
| Molecubes–Bruker: investment, 202111 acquisition €na by Bruker |
2021-11-19 |
| PPF Group–LegoChem: ADC technology, 202111– excl target-specific collab + license agreem up to $1.03b with up to $29.5m near-term for 5 Sotio programs |
2021-11-16 |
| Life Sciences Partners–EQT: investment, 202111– acquisition €450m upfront with €112.5m in cash + €337.5m in shares plus €25m milestone ANNOUNCED |
2021-11-10 |
| Life Sciences Partners–SEVERAL: investment, 202111 announced LSP 7 fund with €850m incl EIF with expected final closing at €1b |
2021-11-04 |
| Mainz Biomed–SEVERAL: investment, 202111 IPO $10m with 2m common shares at $5/share at Nasdaq Capital Market |
2021-11-04 |
| Amarna Therapeutics–Droege Investment: biologics contract manufacturing, 202111c supply production of AMA005 for clinical trials by Halix |
2021-11-01 |
| MDxHealth–SEVERAL: investment, 202110–202111 US IPO $45m+$6.75m of ADSs (each 10 shares) at $12/ADS US listing at Nasdaq Capital Market |
2021-10-28 |
| Origo Biopharma–Agomab Therapeutics: investment, 202110– acquisition €na by Agomab ANNOUNCED |
2021-10-28 |
| Pan Cancer T–Akampion: public relations, 202111 service existent by Akampion |
2021-10-28 |
| Pan Cancer T–Erasmus Univ: investment, 202110 existent founding investor Erasmus MC |
2021-10-28 |
| Pan Cancer T–SEVERAL: investment, 202110 seed financing round expansion €na from new investor Thuja Capital + existing investors |
2021-10-28 |
| Pan Cancer T–Thuja Capital: investment, 202110 seed financing round expansion totalling €na incl new investor Thuja Capital |
2021-10-28 |
| Noxxon–LifeSci: public relations, 202110 service existent LifeSci Advisors is investor/media relations contact |
2021-10-27 |
| DNA Script–Life Sciences Partners: investment, 202110 financing round Series C totalling $165m incl existing + co-investor LSP |
2021-10-26 |
| DNA Script–SEVERAL: investment, 202110 financing round Series C $165m co-led by Coatue Management + Catalio Capital Management |
2021-10-26 |
| TrueMass–Scott Partnership: public relations, 202110 service existent by Scott PR |
2021-10-26 |
| Egle Therapeutics–SEVERAL: investment, 202110 financing round Series A €40m co-led by LSP + InnoBio 2 Fund of Bpifrance |
2021-10-22 |
| Rectify Pharmaceuticals–Forbion: investment, 202110 financing round Series A totalling $100m incl co-lead investor Forbion |
2021-10-14 |
| Rectify Pharmaceuticals–SEVERAL: investment, 202110 financing round Series A $100m co-led by Atlas Venture + Omega Funds + Forbion + Longwood Fund |
2021-10-14 |
| Atbtherapeutics–Trophic Communications: public relations, 202110 service existent by Trophic Communications |
2021-10-05 |
| iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG |
2021-10-05 |
| Biotalys–Consilium: public relations, 202109 service existent by Consilium Strategic Communications |
2021-09-30 |
| Univ Aarhus–Novo Group: grant, 202109–202808 grant DKK630m (€84.7m) to establish NNF CO2 Research Center at AU + six satellite institutes |
2021-09-22 |
| Anjarium Biosciences–Abingworth: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Abingworth |
2021-09-16 |
| Anjarium Biosciences–Gimv: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Gimv |
2021-09-16 |
| Anjarium Biosciences–SEVERAL: investment, 202109 financing round Series A CHF55.5m ($61m) co-led by Abingworth + Gimv |
2021-09-16 |
| Meatable–DSM: cell culture media, 202109– collab developm growth media for cultivated meat |
2021-09-13 |
| Cardior Pharmaceuticals–ABP (NL): investment, 202108 financing round Series B totalling €64m incl new + lead investor Inkef Capital |
2021-08-25 |
| Cardior Pharmaceuticals–Fund+: investment, 202108 financing round Series B totalling €64m incl new + co-investor Fund+ |
2021-08-25 |
| Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital |
2021-08-25 |
| OncXerna Therapeutics–Qiagen: molecular companion diagnostics, 202108– collab developm Xerna TME panel as NGS CDx for navicixizumab |
2021-08-09 |
| Qiagen–OncXerna Therapeutics: molecular companion diagnostics, 202108– license non-excl to Xerna TME panel as NGS CDx for Qiagen |
2021-08-09 |
| Mestag Therapeutics–Forbion: investment, 202108 seed financing round extension totalling $34m incl new + lead investor Forbion |
2021-08-03 |
| Mestag Therapeutics–SEVERAL: investment, 202108 seed financing round extension $34m led by Forbion bringing total seed round to $45m |
2021-08-03 |
| Spectricity–SEVERAL: investment, 202108 financing round Series B €14m |
2021-08-03 |
| T-Knife–SEVERAL: investment, 202108 financing round Series B $110m led by new investor Fidelity Management and Research |
2021-08-02 |
| Topas Therapeutics–Gimv: investment, 202107 financing round Series B extension €18m incl existing investor Gimv |
2021-07-29 |
| Topas Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €18m bringing total round to €40m incl all existing investors |
2021-07-29 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202107 financing round Series B extension €18m incl existing investor Vesalius Biocapital III |
2021-07-29 |
| Artios Pharma–SEVERAL: investment, 202107 financing round Series C £110m ($153m) co-led by Omega Funds + TCG X |
2021-07-27 |
| Axa–SEVERAL: investment, 202107 raising of €1.9b equity by AXA IM Alts to invest in European Life Sciences primarily via Kadans Science Partner |
2021-07-26 |
| Slingshot Biosciences–Anterra Capital: investment, 202107 financing round Series A totalling $23m inc co-investor Anterra Capital |
2021-07-22 |
| Slingshot Biosciences–SEVERAL: investment, 202107 financing round Series A $23m led by Northpond Ventures with ARCH Venture Partners + Anterra Capital |
2021-07-22 |
| Coave Therapeutics–Fund+: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor Fund+ |
2021-07-21 |
| Coave Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €21.2m bringing total Series B to €33.1m |
2021-07-21 |
| Coave Therapeutics–V-Bio Ventures: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor V-Bio Ventures |
2021-07-21 |
| NanoSyrinx–Merck (DE): investment, 202107 seed financing round totalling £6.2m incl existing + co-lead investor M Ventures |
2021-07-19 |
| NanoSyrinx–SEVERAL: investment, 202107 seed financing round £6.2m co-led by Octopus Ventures + M Ventures |
2021-07-19 |
| Nerre Therapeutics–Forbion: investment, 202107 financing round Series B2 totalling £20m incl existing + co-investor Forbion Capital Partners |
2021-07-07 |
| Nerre Therapeutics–SEVERAL: investment, 202107 financing round Series B2 £20m led by Columbus Venture Partners |
2021-07-07 |
| Promethera–SEVERAL: investment, 202106– financing round €20m incl €10m from Shang Ying Intl Holdings Ltd (HK) |
2021-06-30 |
| RheinCell Therapeutics–Catalent: investment, 202106– acquisition of RheinCell by Catalent ANNOUNCED |
2021-06-24 |
| Corlieve Therapeutics–Uniqure: investment, 202106–202107 acquisition €46.3m upfront cash + €203.7m milestones |
2021-06-22 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Fighting Customers 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-fighting-customers.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
